VEGFA and myocardial infarction: Candesartan was shown to inhibit neovascularization in both type 1 diabetic mice and Otsuka Long-Evans Tokushima Fatty rats, a model of human non-insulin-dependent DM [20,42] and had no effects on circulating angiogenic factor VEGF level in patients with acute myocardial infarction [43].